
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PACAP CRISPR/Cas9 KO Plasmid (r) | sc-437378 | 20 µg | $397.00 |
Pituitary adenylate cyclase-activating polypeptide (PACAP; Adcyap1) is a conserved neuropeptide that signals primarily through the PAC1 receptor and can also engage VPAC receptors to regulate cAMP/PKA and MAPK/ERK-dependent transcription. In rat nervous and neuroendocrine systems, PACAP modulates neuronal excitability, neurotransmitter release, stress-axis signaling, and developmental programs including neurite outgrowth and cell survival. PACAP-driven signaling intersects with calcium homeostasis, synaptic plasticity, and inflammatory mediator regulation, linking this pathway to mechanisms relevant to pain processing, stress-related behaviors, and neuroinflammation. Dysregulated PACAP activity has been associated with altered autonomic and metabolic control and has been investigated in models of migraine-like phenotypes and neurodegenerative vulnerability.
PACAP CRISPR/Cas9 KO Plasmid (r) is a pool of plasmids designed for targeted disruption of the gene in rat cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PACAP protein expression.
This CRISPR knockout system enables efficient generation of -deficient cell models for investigation of PACAP signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.